RU2320338C2 - ПРИМЕНЕНИЕ ИНГИБИТОРОВ IkB-КИНАЗЫ ПРИ ОБЕЗБОЛИВАЮЩЕМ ЛЕЧЕНИИ - Google Patents

ПРИМЕНЕНИЕ ИНГИБИТОРОВ IkB-КИНАЗЫ ПРИ ОБЕЗБОЛИВАЮЩЕМ ЛЕЧЕНИИ Download PDF

Info

Publication number
RU2320338C2
RU2320338C2 RU2005107419/15A RU2005107419A RU2320338C2 RU 2320338 C2 RU2320338 C2 RU 2320338C2 RU 2005107419/15 A RU2005107419/15 A RU 2005107419/15A RU 2005107419 A RU2005107419 A RU 2005107419A RU 2320338 C2 RU2320338 C2 RU 2320338C2
Authority
RU
Russia
Prior art keywords
alkyl
pain
formula
compound
substituted
Prior art date
Application number
RU2005107419/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005107419A (ru
Inventor
Мартин МИХАЭЛИС (DE)
Мартин МИХАЭЛИС
Олаф РИТЦЕЛЕР (DE)
Олаф Ритцелер
Герхард ЙЕНЕ (DE)
Герхард ЙЕНЕ
Карл РУДОЛЬФИ (DE)
Карл РУДОЛЬФИ
Герд ГАЙССЛИНГЕР (DE)
Герд ГАЙССЛИНГЕР
Ханс-Георг ШАЙБЛЕ (DE)
Ханс-Георг ШАЙБЛЕ
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Publication of RU2005107419A publication Critical patent/RU2005107419A/ru
Application granted granted Critical
Publication of RU2320338C2 publication Critical patent/RU2320338C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paper (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2005107419/15A 2002-08-17 2003-08-05 ПРИМЕНЕНИЕ ИНГИБИТОРОВ IkB-КИНАЗЫ ПРИ ОБЕЗБОЛИВАЮЩЕМ ЛЕЧЕНИИ RU2320338C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723.5 2002-08-17
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie

Publications (2)

Publication Number Publication Date
RU2005107419A RU2005107419A (ru) 2005-08-10
RU2320338C2 true RU2320338C2 (ru) 2008-03-27

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005107419/15A RU2320338C2 (ru) 2002-08-17 2003-08-05 ПРИМЕНЕНИЕ ИНГИБИТОРОВ IkB-КИНАЗЫ ПРИ ОБЕЗБОЛИВАЮЩЕМ ЛЕЧЕНИИ

Country Status (33)

Country Link
EP (1) EP1531819B1 (enExample)
JP (1) JP4504811B2 (enExample)
KR (2) KR101119845B1 (enExample)
CN (1) CN100398107C (enExample)
AR (1) AR043045A1 (enExample)
AT (1) ATE418336T1 (enExample)
AU (1) AU2003271555B2 (enExample)
BR (1) BR0313555A (enExample)
CA (1) CA2495455C (enExample)
CO (1) CO5690585A2 (enExample)
CR (1) CR7716A (enExample)
CY (1) CY1108874T1 (enExample)
DE (2) DE10237723A1 (enExample)
DK (1) DK1531819T3 (enExample)
EC (1) ECSP055609A (enExample)
ES (1) ES2320118T3 (enExample)
HR (1) HRP20050041B1 (enExample)
IL (1) IL166780A (enExample)
MA (1) MA27334A1 (enExample)
MX (1) MXPA05001218A (enExample)
MY (1) MY138059A (enExample)
NO (1) NO334309B1 (enExample)
OA (1) OA12907A (enExample)
PL (1) PL212356B1 (enExample)
PT (1) PT1531819E (enExample)
RS (1) RS51878B (enExample)
RU (1) RU2320338C2 (enExample)
SI (1) SI1531819T1 (enExample)
TN (1) TNSN05044A1 (enExample)
TW (1) TWI325782B (enExample)
UA (1) UA80837C2 (enExample)
WO (1) WO2004022057A1 (enExample)
ZA (1) ZA200500323B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631320C2 (ru) * 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
SG11201610429YA (en) * 2014-07-03 2017-01-27 Sanofi Sa 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide for use in the treatment of pain associated to osteoarthritis
AU2019304216B2 (en) 2018-07-16 2022-06-02 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1047582B (zh) * 1999-06-23 2005-03-04 萨诺费－阿文蒂斯德国有限公司 取代的苯並咪唑
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631320C2 (ru) * 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты

Also Published As

Publication number Publication date
IL166780A (en) 2011-11-30
WO2004022057A1 (de) 2004-03-18
HK1079426A1 (en) 2006-04-07
KR101119845B1 (ko) 2012-02-28
DK1531819T3 (da) 2009-04-20
CO5690585A2 (es) 2006-10-31
AU2003271555A1 (en) 2004-03-29
CN100398107C (zh) 2008-07-02
JP2005539053A (ja) 2005-12-22
MY138059A (en) 2009-04-30
NO334309B1 (no) 2014-02-03
CA2495455C (en) 2011-01-11
ZA200500323B (en) 2006-02-22
UA80837C2 (uk) 2007-11-12
KR20110135428A (ko) 2011-12-16
MA27334A1 (fr) 2005-05-02
DE50310980D1 (de) 2009-02-05
AR043045A1 (es) 2005-07-13
MXPA05001218A (es) 2005-05-16
PT1531819E (pt) 2009-02-18
TNSN05044A1 (en) 2007-05-14
TWI325782B (en) 2010-06-11
PL373568A1 (en) 2005-09-05
AU2003271555B2 (en) 2009-03-26
NO20051339L (no) 2005-05-03
CA2495455A1 (en) 2004-03-18
TW200417370A (en) 2004-09-16
EP1531819A1 (de) 2005-05-25
ATE418336T1 (de) 2009-01-15
ECSP055609A (es) 2005-04-18
HRP20050041A2 (hr) 2006-04-30
KR20050058339A (ko) 2005-06-16
PL212356B1 (pl) 2012-09-28
DE10237723A1 (de) 2004-07-08
RS20050070A (sr) 2007-06-04
SI1531819T1 (sl) 2009-06-30
RU2005107419A (ru) 2005-08-10
ES2320118T3 (es) 2009-05-19
RS51878B (sr) 2012-02-29
EP1531819B1 (de) 2008-12-24
IL166780A0 (en) 2006-01-15
OA12907A (en) 2006-10-13
CY1108874T1 (el) 2014-07-02
JP4504811B2 (ja) 2010-07-14
BR0313555A (pt) 2005-07-12
CR7716A (es) 2008-11-25
CN1674899A (zh) 2005-09-28
HRP20050041B1 (hr) 2013-07-31

Similar Documents

Publication Publication Date Title
KR101119845B1 (ko) 동통 치료용 ＩκＢ 키나제 억제제의 용도
KR100795709B1 (ko) 치환된 인돌
US8809358B2 (en) Use of IκB-kinase inhibitors in pain therapy
RU2261248C2 (ru) Замещенные бензимидазолы и лекарственное средство на их основе
HK1079426B (en) USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN
NZ538297A (en) Use of IkB kinase inhibitors for the treatment of pain

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160806